107 related articles for article (PubMed ID: 10622598)
1. Cost-effectiveness of treatment for chronic hepatitis C.
Koff RS
J Hepatol; 1999; 31 Suppl 1():255-8. PubMed ID: 10622598
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of combined interferon and ribavirin versus interferon alone.
Koff RS
Clin Liver Dis; 1999 Nov; 3(4):827-41. PubMed ID: 11291253
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
Wong JB; Bennett WG; Koff RS; Pauker SG
JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of interferon treatment for hepatitis C.
van Leeuwen DJ
JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of interferon treatment for hepatitis C.
Henley E
JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
Kuwabara H; Westerhout K; Treur M; Cerri K; Mahlich J; Yatsuhashi H
J Med Econ; 2015; 18(7):502-11. PubMed ID: 25763827
[TBL] [Abstract][Full Text] [Related]
10. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Wong JB; Davis GL; Pauker SG
Am J Med; 2000 Apr; 108(5):366-73. PubMed ID: 10759092
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
13. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Lidgren M; Hollander A; Weiland O; Jönsson B
Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
15. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
16. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
Yoshida H; Tateishi R; Omata M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
[No Abstract] [Full Text] [Related]
19. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
20. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.
Townsend R; McEwan P; Kim R; Yuan Y
Value Health; 2011 Dec; 14(8):1068-77. PubMed ID: 22152176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]